Price
CHART BY
Frequently asked questions
What is Axsome's market capitalization?
The market capitalization of Axsome is $11.56B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Axsome?
Axsome's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.76. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Axsome's stock?
Currently, 23 analysts cover Axsome's stock, with a consensus target price of $283.25. Analyst ratings provide insights into the stock's expected performance.
What is Axsome's revenue over the trailing twelve months?
Over the trailing twelve months, Axsome reported a revenue of $776.57M.
What is the EBITDA for Axsome?
Axsome's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$172.92M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Axsome?
Axsome has a free cash flow of -$71.96M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Axsome have, and what sector and industry does it belong to?
Axsome employs approximately 925 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Axsome's shares?
The free float of Axsome is 44.18M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $11.56B
- EPS (TTM)
- -$3.76
- Free Float
- 44.18M
- Revenue (TTM)
- $776.57M
- EBITDA (TTM)
- -$172.92M
- Free Cashflow (TTM)
- -$71.96M
Pricing
- 1D span
- $215.78$216.70
- 52W span
- $112.98$257.88
Analyst Ratings
The price target is $283.25 and the stock is covered by 23 analysts.
Buy
21
Hold
2
Sell
0
Information
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
- Employees
- 925
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- AXSM
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet